RE: Movement23 May 2024 14:24
In effect there exists 2 areas of news here.
Firstly we have satisfactory safety data allowing SDC1801 to progress to further/later stage trials.
Secondly, we can have detailed feedback on how good the safety data is.
Example 1, Drug has exhibited minimal serious adverse events at doses received in healthy patients. Drug considered satisfactory to progress to later stage of trial.
Example2. Drug administered to healthy volunteers exhibited no Indications of any serious adverse events up to the maximum dose authorised by the trial. Drug considered satisfactory to progress to later stage.
There exists a trade off, as dosing increases so does the risk of adverse events increase.
In the first example to achieve a therapeutically effective dose, the dose when significantly increased is likely to exhibit a significant number of events that prevent dosaging at this level.
This most likely to materialise in phase2 studies where around 2 out of 3 drugs statistically fail.
The 2nd example that gave no indication of any adverse events, can and may have a therapeutic dose increased to give an acceptable level of efficacy with little to no detriment with regards to adverse events.
You should be able to see the advantages of the 2nd example.
In addition there will be if course biomarker and other data indicating areas most likely to benefit from SDC1801. Also a knock on effect as to likelihood of a satisfactory out come on SDC1802.
We may prove highly favourable in SLE where others have failed dismally
'250 Pages Report] The systemic lupus erythematosus (SLE) drugs market is projected to record a CAGR of 5% during the forecast period, up from US$ 183.3 Billion in 2020, to reach a valuation of US$ 329.18 Billion by 2032.'
I will add that Small molecule kinase inhibitors in this area are very seriously being investigated.
Regards
Sign In
Follow the stocks
